InspireMD, Inc. (NSPR)
NASDAQ: NSPR · IEX Real-Time Price · USD
2.010
+0.050 (2.55%)
At close: May 2, 2024, 3:57 PM
1.880
-0.130 (-6.47%)
After-hours: May 2, 2024, 7:47 PM EDT
InspireMD Revenue
In the year 2023, InspireMD had annual revenue of $6.21M with 20.00% growth. Revenue in the quarter ending December 31, 2023 was $1.76M with 71.64% year-over-year growth.
Revenue (ttm)
$6.21M
Revenue Growth
+20.00%
P/S Ratio
7.35
Revenue / Employee
$95,462
Employees
65
Market Cap
47.04M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
Dec 31, 2019 | 3.72M | 120.00K | 3.33% |
Dec 31, 2018 | 3.60M | 840.00K | 30.42% |
Dec 31, 2017 | 2.76M | 867.00K | 45.78% |
Dec 31, 2016 | 1.89M | -416.00K | -18.01% |
Dec 31, 2015 | 2.31M | -508.00K | -18.03% |
Dec 31, 2014 | 2.82M | -2.06M | -42.17% |
Jun 30, 2013 | 4.87M | -476.00K | -8.90% |
Jun 30, 2012 | 5.35M | -655.00K | -10.91% |
Dec 31, 2011 | 6.00M | 1.06M | 21.32% |
Dec 31, 2010 | 4.95M | 1.54M | 45.09% |
Dec 31, 2009 | 3.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nortech Systems | 139.33M |
Rockwell Medical | 83.61M |
IRIDEX | 51.87M |
Cytosorbents | 36.35M |
Daxor | 34.67M |
Renalytix | 2.41M |
Matinas BioPharma Holdings | 1.10M |
NSPR News
- 4 weeks ago - InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 - GlobeNewsWire
- 2 months ago - InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th - GlobeNewsWire
- 2 months ago - InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System - GlobeNewsWire
- 3 months ago - InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework - GlobeNewsWire
- 4 months ago - InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America - GlobeNewsWire
- 4 months ago - InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System - GlobeNewsWire